Editorial & Advertiser disclosure
Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking & Finance Review®
Posted on March 7, 2026
2 min read
Last updated: March 7, 2026
Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports
Table of Contents
Novo Nordisk and Hims & Hers Health End Dispute and Form Partnership
Background of the Dispute
March 6 (Reuters) – Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.
Market Reaction
Hims shares surged 39% in after-hours trading after the report.
Legal and Regulatory Issues
The report comes nearly a month after Novo sued Hims over patent infringement following the U.S. telehealth firm’s launch, and then cancellation, of a $49 copy of Novo’s obesity pill.
The U.S. Food and Drug Administration had also threatened action against Hims.
Details of the New Partnership
Announcement Timeline
Novo and Hims plan to announce a new partnership as soon as Monday, the report said, citing a person familiar with the matter.
Previous Agreements and Marketing Concerns
Last year, Novo ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims over the company’s marketing tactics and continued sales of Wegovy copies.
Statements from Both Companies
A Novo spokesperson said in an e-mailed statement the company is “always in conversation with companies that can help improve patient access to FDA-approved medicines”.
Hims did not immediately respond to a request for comment.
Reporting Credits
(Reporting by Carlos Mendez in Mexico City, additional reporting by Mihika Sharma in Bengaluru; Editing by Himani Sarkar)
